申请人:CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD.
公开号:US20200291012A1
公开(公告)日:2020-09-17
The present application relates to a crystalline sulfamide compound, and in particular relates to a crystalline (S)-N-((S)-1-(2-chlorphenyl)-2-((3,3-difluorocyclobutyl)amido)-2oxoethyl)-2-(4-cyanopyridin-2-base)-N-(3-fluorophenyl)-isothiazolidine-3-formamide 1,1-dioxide, and a preparation method therefor, a crystalline composition, a pharmaceutical composition and uses thereof. An X-ray powder diffraction spectrum of a crystalline hydrate of formula II of the present application has diffraction peaks at positions of about 14.40°, 20.28°, 20.94°, 22.02°, and 24.46°, represented by 2θ. The crystalline hydrate of formula II of the present application has good IDH1 inhibitory activity and performs high stability, and therefore has advantages in physical property, safety and metabolic stability, and has high medicine value.
本申请涉及一种结晶磺胺酰胺化合物,具体涉及一种结晶(S)-N-((S)-1-(2-氯苯基)-2-((3,3-二氟环丁基)氨基)-2-羰基乙基)-2-(4-氰吡啶-2-基)-N-(3-氟苯基)-异噻唑烷-3-甲酰胺1,1-二氧化物,以及其制备方法、结晶组合物、药物组合物及其用途。本申请的公式II的结晶水合物的X射线粉末衍射谱在约14.40°、20.28°、20.94°、22.02°和24.46°的位置具有衍射峰,用2θ表示。本申请的公式II的结晶水合物具有良好的IDH1抑制活性和高稳定性,因此在物理性质、安全性和代谢稳定性方面具有优势,并具有很高的药用价值。